Posts by: Stacy Grieve, PhD

News

A large group study showed that first-generation disease-modifying therapies (DMTs) do not increase the infection risk in multiple sclerosis (MS) patients. Many of the DMTs used ... Read more

September 29, 2017October 3, 2017

Falls Common Among Wheelchair, Scooter Users in People with MS, Study Reports

News

The majority of people living with multiple sclerosis who use wheelchairs or scooters for mobility reported falling at least once over a six-month period, according to ... Read more

August 8, 2017August 8, 2017

Hereditary Gene Mutations Can Be Corrected, Reports Landmark Embryo Study, with Implications for MS

News

For the first time, scientists have shown they can correct gene mutations in human embryos — a breakthrough with implications for multiple sclerosis (MS) and several ... Read more

July 11, 2017July 17, 2017

Long-term Use of Ampyra Lowers Medical Costs, Hospital Visits for MS Patients, Study Finds

News

A recent study has found that continued use of Ampyra (dalfampridine extended-release, sold in the U.S. by Acorda Therapeutics) by patients with multiple sclerosis (MS) lowers ... Read more

March 23, 2017March 23, 2017

Early Rebif Treatment Prolongs Progression to Clinically Definite MS, Study Reports

News

An extension of a Phase 3 clinical trial has shown that early treatment with Rebif (interferon beta-1a) in patients with initial manifestations of multiple sclerosis (MS) ... Read more

Posts by: Stacy Grieve, PhD

Stacy Grieve, PhD

First Generation Disease-modifying Therapies Pose Low Infection Risk in MS, Study Finds

Falls Common Among Wheelchair, Scooter Users in People with MS, Study Reports

Hereditary Gene Mutations Can Be Corrected, Reports Landmark Embryo Study, with Implications for MS

Long-term Use of Ampyra Lowers Medical Costs, Hospital Visits for MS Patients, Study Finds

Early Rebif Treatment Prolongs Progression to Clinically Definite MS, Study Reports

Pin It on Pinterest